• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Inhibition of angiogenesis by internalization inducer

Research Project

Project/Area Number 23590459
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Experimental pathology
Research InstitutionOsaka University

Principal Investigator

NARAZAKI Masashi  大阪大学, 医学(系)研究科(研究院), 助教 (00467573)

Project Period (FY) 2011 – 2013
Project Status Completed (Fiscal Year 2013)
Budget Amount *help
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Keywords血管新生 / Neuropilin-1 / 血管内皮細胞 / 受容体 / Neuropilin1 / VEGF
Research Abstract

We analyzed the inhibitory mechanisms of angiogenesis by using three groups of molecule, including artificial compounds, physiological cytokine, and inhibitory antibody. Neuropilin-1 is a cell surface receptor of VEGF. We showed that sulfate polysaccharide, fucoidan, and oligo-guanosine nucleotide could internalize Neuropilin-1 from the endothelial cell surface to lysosome as an "internalization-inducer". Moreover, we showed that fucoidan and oligo-guanosine nucleotide could inhibit angiogenesis in vivo. We analyzed the interaction of a cytokine VEGF-B with FGF receptor. We proposed the possibility that VEGF-B works as an antagonist of FGF receptor. And we analyzed the biochemical property of the antibody against the members of Ephrin family that are recently identified to have a role in angiogenesis.

Report

(4 results)
  • 2013 Annual Research Report   Final Research Report ( PDF )
  • 2012 Research-status Report
  • 2011 Research-status Report
  • Research Products

    (19 results)

All 2014 2013 2012 2011 Other

All Journal Article (16 results) (of which Peer Reviewed: 14 results) Book (1 results) Remarks (1 results) Patent(Industrial Property Rights) (1 results)

  • [Journal Article] A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.2014

    • Author(s)
      Tanaka T, Narazaki M, Ogata A, Kishimoto T.
    • Journal Title

      Semin Immunol.

      Volume: 26(1) Pages: 88-96

    • Related Report
      2013 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab.2014

    • Author(s)
      Shima Y, Hosen N, Hirano T, Arimitsu J, Nishida S, Hagihara K, Narazaki M, Ogata A, Tanaka T, Kishimoto T, Kumanogoh A.
    • Journal Title

      Mod Rheumatol.

      Volume: Feb 18

    • Related Report
      2013 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Immune reconstitution inflammatory syndrome in a patient with adult-onset Still's disease: Graft-versus-host-like skin reaction with possible asymptomatic human herpes virus reactivation during steroid tapering.2014

    • Author(s)
      Yamaga K, Hanafusa T, Azukizawa H, Tanemura A, Nii T, Nishide M, Narazaki M, Katayama I.
    • Journal Title

      Eur J Dermatol.

      Volume: 24(1) Pages: 101-103

    • Related Report
      2013 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Tocilizumab : An Updated Review of Its Use in the Treatment; Rheumatoid Arthritis and Its Application for Other Immune-Mediated Diseases2013

    • Author(s)
      Tanaka T, Ogata A, and Narazaki M
    • Journal Title

      Clinical Medicine Insights Therapeutics

      Volume: 5 Pages: 33-52

    • Related Report
      2013 Final Research Report
    • Peer Reviewed
  • [Journal Article] Interleukin-6; pathogenesis and treatment of autoimmune inflammatory diseases2013

    • Author(s)
      Tanaka T, Narazaki M, Masuda K, Kishimoto T
    • Journal Title

      Inflammation & Regeneration

      Volume: 33 Pages: 54-65

    • NAID

      130004943832

    • Related Report
      2013 Final Research Report
  • [Journal Article] Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis.2013

    • Author(s)
      Hishitani Y, Ogata A, Shima Y, Hirano T, Ebina K, Kunugiza Y, Shi K, Narazaki M, Hagihara K, Tomita T, Yoshikawa H, Tanaka T, Kumanogoh A.
    • Journal Title

      Scand J Rheumatol.

      Volume: 42(4) Pages: 253-259

    • Related Report
      2013 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Interleukin-6; pathogenesis and treatment of autoimmune inflammatory diseases.2013

    • Author(s)
      Tanaka T, Narazaki M, Masuda K, Kishimoto T.
    • Journal Title

      Inflammation & Regeneration.

      Volume: 33 Pages: 54-65

    • NAID

      130004943832

    • Related Report
      2012 Research-status Report
  • [Journal Article] Tocilizumab: An Updated Review of Its Use in the Treatment; Rheumatoid Arthritis and Its Application for Other Immune-Mediated Diseases. Clinical Medicine Insights2013

    • Author(s)
      Tanaka T, Ogata A, and Narazaki M.
    • Journal Title

      Therapeutics

      Volume: 5 Pages: 33-52

    • Related Report
      2012 Research-status Report
    • Peer Reviewed
  • [Journal Article] Therapeutic targeting of the interleukin-6 receptor2012

    • Author(s)
      Tanaka T, Narazaki M, Kishimoto T
    • Journal Title

      Annu Rev Pharmacol Toxicol

      Volume: 52 Pages: 199-219

    • Related Report
      2013 Final Research Report
    • Peer Reviewed
  • [Journal Article] Therapeutic implications of tocilizumab, a humanized anti-interleukin-6 receptor antibody, for various immune-mediated diseases: an update review.2012

    • Author(s)
      Tanaka T, Ogata A, Shima Y, Narazaki M, Kumanogoh A and Kishimoto T.
    • Journal Title

      Curr Rheumatol Rev

      Volume: 8 Pages: 209-226

    • Related Report
      2012 Research-status Report
    • Peer Reviewed
  • [Journal Article] A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.2012

    • Author(s)
      Hirano T, Ohguro N, Hohki S, Hagihara K, Shima Y, Narazaki M, Ogata A, Yoshizaki K, Kumanogoh A, Kishimoto T, Tanaka T.
    • Journal Title

      Mod Rheumatolol

      Volume: 22(2) Pages: 298-302

    • Related Report
      2012 Research-status Report
    • Peer Reviewed
  • [Journal Article] Therapeutic targeting of the interleukin-6 receptor.2012

    • Author(s)
      Tanaka T, Narazaki M, Kishimoto T.
    • Journal Title

      Annu Rev Pharmacol Toxicol.

      Volume: 52 Pages: 199-219

    • Related Report
      2011 Research-status Report
    • Peer Reviewed
  • [Journal Article] Therapeutic effect of tocilizumab on two patients with polymyositis2011

    • Author(s)
      Narazaki M, Hagihara K, Shima Y, Ogata A, Kishimoto T, Tanaka T
    • Journal Title

      Rheumatology (Oxford)

      Volume: 50(7) Pages: 1344-1346

    • Related Report
      2013 Final Research Report
    • Peer Reviewed
  • [Journal Article] Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases2011

    • Author(s)
      Tanaka T, Narazaki M, Kishimoto T
    • Journal Title

      FEBS Lett

      Volume: 585(23) Pages: 3699-3709

    • Related Report
      2013 Final Research Report
    • Peer Reviewed
  • [Journal Article] Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases.2011

    • Author(s)
      Tanaka T, Narazaki M, Kishimoto T.
    • Journal Title

      FEBS Lett.

      Volume: 585(23) Pages: 3699-3709

    • Related Report
      2011 Research-status Report
    • Peer Reviewed
  • [Journal Article] Therapeutic effect of tocilizumab on two patients with polymyositis.2011

    • Author(s)
      Narazaki M, Hagihara K, Shima Y, Ogata A, Kishimoto T, Tanaka T.
    • Journal Title

      Rheumatology (Oxford).

      Volume: 50(7) Pages: 1344-1346

    • Related Report
      2011 Research-status Report
    • Peer Reviewed
  • [Book] 免疫学コア講義改訂3版2012

    • Author(s)
      熊ノ郷淳他編
    • Publisher
      南山堂
    • Related Report
      2013 Final Research Report
  • [Remarks]

    • URL

      http://www.med.osaka-u.ac.jp/pub/imed3/lab_2/page6/summary.html

    • Related Report
      2013 Final Research Report
  • [Patent(Industrial Property Rights)] New hetero-bifunctional ligand comprises target receptor-binding agent, heterologous internalizing receptor-binding agent, and linker, useful for inducing internalization of target receptor, and for treating or inhibiting an HIV infection2013

    • Inventor(s)
      Narazaki M, Tosato G
    • Industrial Property Rights Holder
      US dept health&human services
    • Filing Date
      2013-04-16
    • Related Report
      2013 Final Research Report

URL: 

Published: 2011-08-05   Modified: 2019-07-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi